EP
BMRN icon

Essential Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Essential Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Sell
3,131
-5,646
-64% -$309K 0.08% 260
2026
Q1 		$496K Sell
8,777
-8,843
-50% -$516K 0.17% 149
2025
Q4 		$1.05M Buy
17,620
+3,400
+24% +$185K 0.32% 83
2025
Q3 		$770K Sell
14,220
-4,105
-22% -$235K 0.25% 107
2025
Q2 		$1.01M Buy
+18,325
New +$1.08M 0.4% 61

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Essential Partners's BMRN Position: Q2 2026 in Review

Essential Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 64% in Q2 2026, selling an estimated $309K and leaving 3,131 shares worth $179K. The position accounts for 0.08% of the portfolio, ranked #260.

Essential Partners first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.05M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Essential Partners held 3,131 shares of BioMarin Pharmaceuticals worth $179K as of Q2 2026.
  • Essential Partners sold 5,646 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $309K.
  • BioMarin Pharmaceuticals made up 0.08% of Essential Partners's portfolio in Q2 2026, its #260 holding.
  • Essential Partners first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's BioMarin Pharmaceuticals position peaked at $1.05M in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.